NEW YORK, May 31, 2026, 17:04 EDT
- TScan ended Friday at $1.08. Trading was light during the shortened holiday week.
- Investors wait for second-quarter ALLOHA data and the expected Phase 3 kickoff for TSC-101.
- The May 22 filing showed shareholders backed an increase in authorized voting common shares to 600 million, doubling the amount.
TScan Therapeutics (TCRX) heads into June as investors wait for the next clinical update. Shares ended Friday at $1.08, with trading volume light ahead of the weekend and U.S. markets closed. The stock moved between $1.04 and $1.13 through the shortened week, historical data from the company showed.
TScan is flagging early data for Cohort C in its ALLOHA Phase 1 blood-cancer trial for the second quarter and also says it wants to start a Phase 3 trial of TSC-101 in that same quarter. A Phase 3 trial is late-stage and usually backs a regulatory filing.
TScan isn’t talking revenue yet—it’s about data and cash. The company held $128.1 million in cash and cash equivalents as of March 31, not counting $5 million in restricted cash, and says the balance should cover its operations into the second half of 2027.
Nasdaq closed for Memorial Day on May 25, leaving last week with just four trading days. Regular hours are 9:30 a.m. to 4:00 p.m. ET, Monday through Friday. Juneteenth, on June 19, is shown as the next 2026 holiday in Nasdaq’s calendar.
TScan is working on TCR-T therapies, or T cell receptor-engineered T cell treatments, made to help immune cells find cancer targets. The main program focuses on stopping relapse after allogeneic hematopoietic cell transplant in blood cancer patients.
TScan CEO Gavin MacBeath said “2026 will be a critical year for TScan,” as the company gets ready for its planned Phase 3 TSC-101 trial in AML and MDS patients set for transplant. Chief Medical Officer Chrystal Louis said TScan wants to “continue to build our heme franchise,” with two CD45-targeted programs aiming for a Phase 1 start in the second half. GlobeNewswire
TScan has put out another filing for investors to look at. According to a May 22 8-K, shareholders gave the nod to an amendment that boosts the authorized voting common stock count to 600 million shares, up from 300 million. This doesn’t automatically mean new shares hit the market, but it does allow TScan to issue stock or use equity for company needs down the road.
TScan reported a $28.7 million net loss for the first quarter, better than the $34.1 million loss last year. R&D expenses dropped to $21.9 million from $29.8 million. Still, spending stayed high.
Biotechs were quiet on Friday. The Nasdaq Biotechnology Index slipped 0.10% to 5,989.81. TScan’s action looked like a name story rather than a trade tied to the group.
Immatics is moving, too. The Nasdaq-traded TCR biotech said Saturday it shared new Phase 1 results for its PRAME TCR T-cell therapy at the ASCO meeting. It’s another sign investor focus is sticking to clinical data, not sales.
TScan warned its cash won’t last through regulatory approval for its candidates and said it might need a big capital raise. New equity or convertible debt would dilute current holders, and setbacks like trial delays, disappointing data or trouble enrolling patients could drag shares lower.
TScan traders will watch this week for any extra word on Cohort C or the Phase 3 launch before the quarter runs out. No new detail, and the stock might just stick with the usual small-cap biotech moves. Friday’s close was $1.08. That’s where traders will start the week on Monday.
